N-Gene Research Laboratories, Inc.
🇺🇸United States
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Phase 2
Terminated
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: BGP-15 100 mg QDDrug: BGP-15 100 mg BIDDrug: BGP-15 400 mg QDDrug: BGP-15 200 mg QDDrug: BGP-15 200 mg BIDDrug: Placebo BID
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- N-Gene Research Laboratories, Inc.
- Target Recruit Count
- 196
- Registration Number
- NCT01069965
- Locations
- 🇺🇸
Medstar Health Research Institute, Hyattsville, Maryland, United States
🇺🇸The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States
🇺🇸Southeastern Research Associates, Inc., Taylors, South Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath